Molecular hydrogen as a potential mediator of the antitumor effect of inulin consumption
Pascal-Moussellard V, Alcaraz JP, Tanguy S, Salomez-Ihl C, Cinquin P, Boucher F, Boucher E. · Scientific reports. 2025;15(1):11482.
What kind of evidence is this?
Preclinical
Randomized blinded controlled study
Cancer research
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
mice, mouse, cell, cells used to study cancer research.
Preclinical study; the full text reports 6 mice, with group/assay counts including n=6, n=3.
375 mL/min
Full text reports inhaled H₂-containing gas plus H₂ dissolved in drinking water plus topical or bath exposure to H₂-containing water. Detected intervention quantities or schedules: 100 ppm, 375 mL/min, 3%, 76%, 21%.
Inhaled molecular H₂ at 3%; oxygen co-delivery is reported.
H₂-related quantities reported in the intervention passages: 100 ppm, 375 mL/min, 3%, 76%, 21%. Values are not combined across different experimental arms.
11.25 mL/min H₂, calculated from 3% H₂ and 375 mL/min total flow reported in the full text.
21% O₂; 78.75 mL/min O₂ calculated from the reported total flow.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “These results suggest that inulin and H_2 exposure induce a similar antitumor effect through stimulation of immunosurveillance..” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 40181080 · DOI: 10.1038/s41598-025-96346-3
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10